Lenvatinib plus pembrolizumab (L plus P) vs sunitinib (S) in advanced renal cell carcinoma (aRCC): Patterns of progression and subsequent therapy in the CLEAR trial

被引：0
|
作者：
Grunwald, Viktor
Motzer, Robert J.
Keizman, Daniel
Bedke, Jens
Schmidinger, Manuela
Staehler, Michael D.
Matveev, Vsevolod B.
George, Saby
Hutson, Thomas E.
Vaishampayan, Ulka N.
Merchan, Jaime R.
Eto, Masatoshi
Rha, Sun Young
Waddell, Tom
Sabbatini, Roberto
Barthelemy, Philippe
Burgents, Joseph E.
Ren, Min
Brown, Ian
Choueiri, Toni K.
机构：
[1] Univ Hosp Essen, Essen, Germany
[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[3] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel
[4] Klinikum Stuttgart, Dept Urol, Stuttgart, Germany
[5] Klinikum Stuttgart, Eva Mayr Stihl Canc Ctr, Stuttgart, Germany
[6] Med Univ Vienna, Vienna, Austria
[7] Univ Hosp Munich, Munich, Germany
[8] Minist Hlth Russian Federat, State Budgetary Inst NN Blokhin Natl Med Res Ctr, Moscow, Russia
[9] Roswell Park Canc Inst, Buffalo, NY 14263 USA
[10] Texas Oncol, Dallas, TX USA
[11] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI 48109 USA
[12] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[13] Kyushu Univ, Fukuoka, Japan
[14] Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Seoul, South Korea
[15] Christie NHS Fdn Trust, Manchester, Lancs, England
[16] Univ Hosp Modena, Modena, Italy
[17] Strasbourg European Canc Inst, Strasbourg, France
[18] Merck & Co Inc, Rahway, NJ 07065 USA
[19] Eisai Inc, Nutley, NJ USA
[20] Eisai Ltd, Hatfield, Herts, England
[21] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4524
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Re: Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
    Teh, Jiasian
    Narasimhan, Vignesh
    Schultz, Stephen
    Sathianathen, Niranjan
    Murphy, Declan G.
    EUROPEAN UROLOGY, 2019, 76 (01) : 126 - 127
  • [32] A Phase IB/II Trial of Lenvatinib plus Pembrolizumab in Patients With Renal Cell Carcinoma
    Lee, Chung-Han
    Makker, Vicky
    Rasco, Drew
    Taylor, Matthew
    Dutcus, Corina
    Shumaker, Robert
    Schmidt, Emmett
    Stepan, Daniel E.
    Li, Di
    Young, Louise
    Motzer, Robert
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 153 - 153
  • [33] Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Analysis of progression after first subsequent therapy in KEYNOTE-426.
    Powles, Thomas
    Plimack, Elizabeth R.
    Stus, Viktor
    Waddell, Tom
    Gafanov, Rustem
    Pouliot, Frederic
    Nosov, Dmitry
    Melichar, Bohuslav
    Soulieres, Denis
    Borchiellini, Delphine
    Vynnychenko, Ihor
    McDermott, Raymond S.
    Azevedo, Sergio Jobim
    Tamada, Satoshi
    Kryzhanivska, Anna
    Li, Chenxiang
    Burgents, Joseph E.
    Molife, L. Rhoda
    Rini, Brian I.
    Bedke, Jens
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [34] Pembrolizumab plus lenvatinib (P plus L) versus alternative therapies in first-line (1L) advanced renal cell carcinoma (aRCC) by IMDC risk status: A network meta-analysis (NMA).
    Rane, Pratik
    Yan, Kevin
    Schmidinger, Manuela
    Peer, Avivit
    Druyts, Eric
    Burgents, Joseph E.
    Sundaram, Murali
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 421 - 421
  • [35] Biomarker analyses from the phase III CheckMate 214 trial of nivolumab plus ipilimumab (N plus I) or sunitinib (S) in advanced renal cell carcinoma (aRCC).
    Motzer, Robert J.
    Choueiri, Toni K.
    McDermott, David F.
    Powles, Thomas
    Yao, Jin
    Ammar, Ron
    Papillon-Cavanagh, Simon
    Saggi, Shruti S.
    McHenry, Brent M.
    Ross-Macdonald, Petra
    Wind-Rotolo, Megan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [36] Nivolumab plus cabozantinib (N plus C) vs sunitinib (S) for advanced renal cell carcinoma (aRCC): outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial
    Bedke, J.
    Powles, T.
    Burotto, M.
    Bourlon, M. T.
    Hsieh, J. J.
    Basso, U.
    Shah, A. Y.
    Suarez, C.
    Porta, C.
    Barrios, C.
    Gurney, H.
    Kessler, E. R.
    Retz, M.
    George, S.
    Escudier, B.
    Zhang, J.
    Simsek, B.
    Scheffold, C.
    Motzer, R. J.
    Choueiri, T. K.
    Apolo, A. B.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 24 - 25
  • [37] Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC).
    Motzer, Robert J.
    Porta, Camillo
    Alekseev, Boris
    Rha, Sun Young
    Choueiri, Toni K.
    Mendez-Vidal, Maria Jose
    Hong, Sung-Hoo
    Kapoor, Anil
    Goh, Jeffrey C.
    Eto, Masatoshi
    Wang, Jinyi
    Pan, Janice
    Asfaw, Alemseged Ayele
    He, Cixin Steven
    Mody, Kalgi
    Cella, David
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [38] Subgroup analysis from JAVELIN Renal 101: Outcomes for avelumab plus axitinib (A plus Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).
    Choueiri, Toni K.
    Motzer, Robert J.
    Campbell, Matthew T.
    Alekseev, Boris Y.
    Uemura, Motohide
    Kollmannsberger, Christian K.
    Gravis, Gwenaelle
    Bjarnason, Georg A.
    Gurney, Howard
    Chung, Jinsoo
    Haanen, John B. A. G.
    Rini, Brian I.
    Larkin, James M. G.
    Schmidinger, Manuela
    Nole, Franco
    Chudnovsky, Aleksander
    Huang, Bo
    Hariharan, Subramanian
    di Pietro, Alessandra
    Albiges, Laurence
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [39] Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms (vol 13, 1223282, 2023)
    Grunwald, Viktor
    Powles, Thomas
    Eto, Masatoshi
    Kopyltsov, Evgeny
    Rha, Sun Young
    Porta, Camillo
    Motzer, Robert
    Hutson, Thomas E.
    Mendez-Vidal, Maria Jose
    Hong, Sung-Hoo
    Winquist, Eric
    Goh, Jeffrey C.
    Maroto, Pablo
    Buchler, Tomas
    Takagi, Toshio
    Burgents, Joseph E.
    Perini, Rodolfo
    He, Cixin
    Okpara, Chinyere E.
    McKenzie, Jodi
    Choueiri, Toni K.
    FRONTIERS IN ONCOLOGY, 2024, 13
  • [40] Avelumab plus axitinib (A plus Ax) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC): Subgroup analyses by age from the final analysis of the phase III JAVELIN Renal 101 trial
    Oya, M.
    Motzer, R. J.
    Choueiri, T. K.
    Haanen, J. B. A. G.
    Eto, M.
    Uemura, H.
    Venugopal, B.
    Rini, B. I.
    Miyake, H.
    Albiges, L.
    Schmidinger, M.
    Tomita, Y.
    Umeyama, Y.
    Ellers-Lenz, B.
    Hoffman, J.
    Larkin, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S1517 - S1518
12345